References
hypoglycemia, weight gain
HYPOGLYCEMIA, ADVERSE EVENT, INSULIN RESISTANCE
Changes in glycemic parameters after gemigliptin–metformin or glimepiride–metformin combination therapies during the study period, and the proportion of participants who achieved the glycemic target of HbA1c ≤7.0% (53 mmol/mol) without hypoglycemia or weight gain. (Changes in the microbiota profiles of bacterial phyla with gemigliptin–metformin or glimepiride–metformin combination therapies at the baseline and at the end of the study. (Baseline characteristics of the intention-to-treat study population.Data are the mean ± SD or n (%). Key: SBP, systolic blood pressure; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker.Investigational parameters at the baseline and after 24 weeks of treatment.* Values compared after logarithmic transformation. Key: AUC, area under the curve; HOMA-IR, homeostatic model assessment for insulin resistance; PAI, plasminogen activator inhibitor; hsCRP, high-sensitivity c-reactive protein; VFA, visceral fat area.Adverse events in both groups observed during the 24 weeks of treatment.Data are 